Efficacy and safety of tolebrutinib (SAR442168) tablets in adult participants with generalized myasthenia gravis

Trial Identifier: EFC17262
Sponsor: Sanofi
Start Date: December 2021
Primary Completion Date: February 2023
Study Completion Date: February 2023
Condition: Myasthenia Gravis

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Canada, Alberta Edmonton, Alberta, Canada, T6G 2B7
Canada, Ontario London, Ontario, Canada, N6A 5A5
China Chengdu, China, 610041
China Shanghai, China, 200040
China Wuhan, China, 430030
Hungary Pécs, Hungary, 7623
Hungary Szeged, Hungary, 6725
Italy Roma, Italy, 00168
Italy, Lombardia Milano, Lombardia, Italy, 20133
Italy, Milano Milano, Italy, 20132
Italy, Napoli Napoli, Italy, 80131
Japan, Kanagawa Sagamihara-shi, Kanagawa, Japan, 252-0392
Poland Zabrze, Poland, 41-800
Spain, Catalunya [Cataluña] Hospitalet de Llobregat, Catalunya [Cataluña], Spain, 08907
Spain, Madrid, Comunidad de Madrid, Madrid, Comunidad de, Spain, 28046
United Kingdom, Devon EXETER, Devon, United Kingdom, EX2 5DW
United Kingdom, Liverpool Liverpool, United Kingdom, L9 7LJ
United States, District of Columbia Washington, DC, District of Columbia, United States, 20007
United States, Florida Boca Raton, Florida, United States, 33487
United States, Florida Tampa, Florida, United States, 33612-6601
United States, Massachusetts Boston, Massachusetts, United States, 02115
United States, Texas San Antonio, Texas, United States, 00000